Graves’ Orbitopathy

A Multidisciplinary Approach – Questions and Answers

3rd, revised and expanded edition

Editors

Wilmar M. Wiersinga  Amsterdam
George J. Kahaly  Mainz

116 figures, 69 in color, and 52 tables, 2017
Contents

xv Preface to the Third, Revised and Expanded Edition
Wiersinga, W.M. (Amsterdam); Kahaly, G.J. (Mainz)

xvi Preface to the Second, Revised Edition
Wiersinga, W.M. (Amsterdam); Kahaly, G.J. (Mainz)

xvi Preface to the First Edition
Wiersinga, W.M. (Amsterdam); Kahaly, G.J. (Mainz)

Diagnosis and Pathogenesis

1 Clinical Manifestations
Dickinson, A.J. (Newcastle upon Tyne); Hintschich, C. (Munich)

1 What Are the Common Signs and Symptoms of Early Graves’ Orbitopathy?
1 What Are Other Signs and Symptoms of Graves’ Orbitopathy?
3 What Signs Should Question the Diagnosis of Graves’ Orbitopathy?
3 Are There Racial Differences in How Graves’ Orbitopathy Manifests?
4 Is the Presentation of Graves’ Orbitopathy Different in Older Compared to Younger Patients?
4 Why Can the Clinical Presentation of Graves’ Orbitopathy Be So Variable?
5 Can You Give Me a Short Mechanistic Explanation for All These Clinical Manifestations?
6 What Do the Terms “Activity” and “Severity” Denote?
7 Why Is It Important to Distinguish Activity and Severity when Evaluating Patients?
7 What Signs and Symptoms Are Valuable for Assessing Activity?
7 How Are These Signs Assessed?
10 How Reproducible Are These Assessments?
11 What Value Does the “Clinical Activity Score” Have?
11 Do Patients without Signs of Activity Ever Have Active Disease?
12 What Should I Do if I Am Not Sure whether the Disease Is Active?
12 Are There Any Other Ways to Evaluate Activity other than Clinical Examination?
13 When Should These Other Methods for Assessing Activity Be Used in Routine Clinical Practice?
14 What Signs Are Helpful for Assessing Severity?
14 What Value Does the Mnemonic “NOSPECS” Have?
14 How Are Signs of Severity Assessed?
18 How Reproducible Are These Assessments?
19 How Is Severity Best Classified?
19 How Do You Decide whether a Patient Has Dysthyroid Optic Neuropathy?
21 Can Dysthyroid Optic Neuropathy Ever Be Present with Normal Vision?
21 Are Some Patients at Particular Risk?
21 What Other Assessments Are Useful in Evaluating Possible Dysthyroid Optic Neuropathy?
22 Should These Tests Be Performed in All Patients at Every Assessment?
22 Are There Any Other Assessment Systems in Common Use?
23 References
26 Orbit-Thyroid Relationship
Marinò, M. (Pisa)

26 Should This Condition Always Be Called Graves’ Orbitopathy?
26 Is Graves’ Orbitopathy Exclusively Occurring in Patients with Graves’ Hyperthyroidism?
28 Do All Patients with Graves’ Hyperthyroidism Have Graves’ Orbitopathy?
28 Are There Any Relationships between Hyperthyroidism, Hypothyroidism, and Graves’ Orbitopathy?
29 Is Graves’ Orbitopathy Related to Thyroid Autoimmunity?
29 Are There Other Extrathyroidal Manifestations of Graves’ Disease apart from Graves’ Orbitopathy?
31 References

33 Epidemiology
Burlacu, M.-C.; Daumerie, C. (Brussels)

33 What Is the Estimated Incidence and Prevalence of Graves’ Orbitopathy?
34 Has the Occurrence of Graves’ Orbitopathy Changed over the Last Few Decades?
35 Is the Age and Sex Distribution of Graves’ Orbitopathy Similar to That of Graves’ Hyperthyroidism?
36 Are There Ethnic Differences?
36 What Are the Risk Factors for the Occurrence of Graves’ Orbitopathy?
37 Can Particular Drugs Trigger or Modify Graves’ Orbitopathy and Its Course?
38 Is Tobacco Bad for Graves’ Orbitopathy?
38 Has Nutrition an Effect on Graves’ Orbitopathy?
38 Does Total Thyroidectomy for Other Diseases than Graves’ Disease Preclude the Development of Graves’ Orbitopathy?
39 References

41 Pathogenesis
Salvi, M. (Milan); Berchner-Pfannschmidt, U. (Essen); Ludgate, M. (Cardiff)

41 What Are the Pathological Changes in Orbital Tissue in Graves’ Orbitopathy?
43 How Do the Pathological Changes Give Rise to the Clinical Manifestations?
44 What Triggers Graves’ Orbitopathy?
45 Is Graves’ Orbitopathy Triggered by an Autoimmune Phenomenon? If So, What Is the Nature of the Autoantigen?
47 Why Is the Orbit Special and a Target for Thyroid Autoimmunity?
48 What Kind of Immune Reactions Take Place within the Orbit?
50 Does Thyroid-Stimulating Hormone Receptor Activation and/or Autoreactivity to Thyroid-Stimulating Hormone Receptor Play a Role in the Onset or Development of Graves’ Orbitopathy?
52 Is There a Familial Predisposition or a Specific Genetic Background for Graves’ Orbitopathy?
53 How Do Environmental Factors Increase the Risk and Severity of Graves’ Orbitopathy?
54 How May These Observations and Current Understanding Lead to More Effective Treatment of Graves’ Orbitopathy?
56 References

61 Orbital Imaging
Pitz, S.; Müller-Forell, W. (Mainz)

61 Is Orbital Imaging Always Necessary?
61 What Are the Relative Benefits of Orbital CT and MRI?
65 What Is Apical Crowding?
68 What Is the Place of Orbital Ultrasound?
70 What Lessons Can We Learn from Orbital Octreoscan?
70 What Other Imaging Techniques May Be Useful?
71 References
74 Diagnosis and Differential Diagnosis of Graves’ Orbitopathy
    Konuk, O. (Ankara); Anagnostis, P. (Thessaloniki)

74 Can You Give an Overall Scheme for the Diagnosis of Graves’ Orbitopathy?
75 Which Clinical Findings Are Helpful in Making a Diagnosis of Graves’ Orbitopathy?
81 Can One Make a Diagnosis of Graves’ Orbitopathy Based on Medical History and Clinical Picture Alone?
82 Do We Always Need to Order Thyroid Autoantibody and Thyroid Function Tests?
83 Which Imaging Technique Is Best to Make a Diagnosis of Graves’ Orbitopathy, and Is Imaging Always Requested?
84 Which Are the Most Frequent Conditions Mimicking Graves’ Orbitopathy?
91 References

93 Natural History
    Mamoojee, Y.; Pearce, S.H.S. (Newcastle upon Tyne)

93 Does Graves’ Orbitopathy Occur at the Same Time as Hyperthyroidism?
94 Does Restoring Euthyroidism Lead to Improvement in Graves’ Orbitopathy?
95 What Effect May Hypothyroidism Have?
95 What Is the Typical Course of the Disease?
96 What Happens to Orbital Fat during the Course of the Disease?
97 What Is the Difference between Activity and Severity?
99 How Do You Determine Which Phase of the Disease the Patient Is Displaying?
99 How Does the Phase of the Disease Influence the Choice of Treatment?
100 Will Graves’ Orbitopathy Eventually Burn Itself Out?
100 Will the Orbital Changes Return to Normal when the Condition Eventually Resolves?
100 How Long Is It Likely to Take before the Disease Becomes Inactive?
101 Once the Condition Has Become Inactive (whether Treated or Untreated), Is It Likely to Flare Up Again?
101 Are There Any Other Factors, Additional to Thyroid Status, That May Influence the Course of the Disease?
102 References

Management

105 General Management Plan for Graves’ Orbitopathy
    Bartalena, L. (Varese)

105 Is There General Agreement among Specialists on How to Manage Graves’ Orbitopathy?
105 What Are the Priorities when Faced with a New Presentation of Graves’ Orbitopathy?
107 Should the Patient Be Informed about Risk Factors Affecting the Course of Graves’ Orbitopathy?
108 What Is the Evidence about the Role of Smoking on the Course of Graves’ Orbitopathy?
109 Does Thyroid Status Affect Graves’ Orbitopathy?
109 Are There Simple Measures That Can Help the Eyes?
110 Is Early Referral to Specialized Centres Important?
111 Can You Provide the Patient with an Overall Management Scheme?
111 References

113 Combined Thyroid-Eye Clinics
    Törüner, F.B.; Konuk, O.; Ayvaz, G. (Ankara)

113 What Are Combined Thyroid-Eye Clinics?
115 Why Is a Multidisciplinary Approach Recommended?
211 Orbital Decompression
Baldeschi, L. (Brussels); Morris, D.S. (Cardiff)

211 What Is Orbital Decompression?
211 What Are the Aims of Orbital Decompression?
215 What Are the Different Types of Orbital Decompression?
223 What Are the Possible Complications of Orbital Decompression?
224 Can Complications Be Predicted or Prevented?
225 Are Technical Developments in Decompression Surgery and Other Surgical Rehabilitative Procedures for Graves' Orbitopathy to Be Expected?
226 Are Conceptual Developments in Decompression Surgery and Other Surgical Rehabilitative Procedures for Graves' Orbitopathy to Be Expected?
227 References

230 Eye Muscle Surgery
Nardi, M. (Pisa); Eckstein, A. (Essen)

230 What Are the Reasons for Impairment of Ocular Motility in Graves' Orbitopathy?
230 Which Muscles Are Involved?
231 How Does Decompression Influence Ocular Motility?
232 How Do You Identify the Affected Muscles?
234 How Can You Avoid Diagnostic Errors in Complex Cases?
236 What Is the Optimal Pretreatment before You Start Eye Muscle Surgery?
236 When Is the Right Time for Surgery?
236 How Do You Deal with Diplopia until Surgery Is Possible?
237 How Can You Evaluate the Need for Surgery?
238 The Surgical Plan: What Procedures Are Recommended?
241 What Are the Possible Complications of Surgery and How Can I Avoid or Manage Them?
243 What Can You Realistically Expect from Surgery?
243 How Can Success of Surgery Be Measured?
244 How Should You Advise the Patient?
244 References

247 Eyelid Surgery
Clarke, L. (Newcastle upon Tyne); Eckstein, A. (Essen)

247 What Are the Indications for Eyelid Surgery in Patients with Graves' Orbitopathy?
248 Is Botulinum Toxin Useful?
249 Is Surgical Intervention Indicated in Corneal Ulceration Secondary to Exposure Keratopathy?
250 Does Orbital Decompression Have Any Effect on Lid Retraction?
250 Does Squint Surgery Influence the Lid Configuration?
251 Can Decompression Be Combined with Lid Lengthening?
252 What Surgical Procedures Are Available for Correction of Upper Lid Retraction?
254 Are There Complications?
254 What Surgical Procedures Are Available for Correction of Lower Lid Retraction?
255 Should This Be Combined with Horizontal Lid Tightening?
256 Which Materials Are Suitable for Use as Spacers? Should the Use of Allogeneic Grafts Be Avoided?
257 Are There Complications?
257 What about Upper Lid Debulking and Upper and Lower Lid Blepharoplasty?
257 Does Lid Surgery Improve the Quality of Life of the Patients?
257 How Can the Effect of Lid Surgery Be Quantified?
258 References
260 **Quality of Life**  
Wiersinga, W.M. (Amsterdam)

260 What Is Quality of Life?  
260 What Is the Usefulness of Quality of Life Measurements?  
262 What Is Known about General Health-Related Quality of Life in Graves’ Orbitopathy?  
263 Is There a Graves’ Orbitopathy-Specific Quality of Life Questionnaire?  
265 What Are the Results of the GO-QoL?  
265 Can You Explain Response Shift in Quality of Life?  
266 Can GO-QoL Be Used as a Separate Outcome Measurement in Graves’ Orbitopathy?  
267 What Is the Experience with GO-QoL as Outcome Measurement in the Literature?  
268 Are There Other Disease-Specific Quality of Life Questionnaires for Graves’ Orbitopathy?  
270 Are There Qualitative Studies on Quality of Life in Graves’ Orbitopathy?  
271 What Can I Conclude and Should I Apply the GO-QoL in My Own Practice?  

275 **Socioeconomic Impact**  
Kahaly, G.J. (Mainz)

275 Is There an Actual Cost Estimation of Thyroid Disorders in Germany and/or Europe?  
276 Does Graves’ Orbitopathy Lead to Occupational Disability?  
276 How Were Data Obtained on Occupational Disability and Impaired Earning Capacity in Graves’ Orbitopathy?  
277 What Are the Findings of the Performed Prospective Study?  
279 How Should We Interpret the Data Obtained on Occupational Disability and Impaired Earning Capacity in Patients with Graves’ Orbitopathy?  
279 What Are the Relevant Implications for the Daily Clinical Practice?  
280 Do We Have Data on the Public Health Relevance of Graves’ Orbitopathy?  
283 References

285 **The Patient’s View**  
von Arx, G. (Olten); Ayvaz, G. (Ankara)

285 Due to the Changes of My Eyes and Skin I Have Not Only “Lost My Face”! Where Can I Get Support and Help?  
286 Will the Treatment for the Thyroid Make the Eyes Better or Worse?  
286 Can Graves’ Orbitopathy Be Prevented?  
287 Will My Eyes Always Get Worse?  
287 What Can Be Done about Common Eye Symptoms of Graves’ Orbitopathy?  
288 Will the Eyes Go Back to Normal?  
288 The Changes in My Face Have Affected Me Badly. Can Anything Be Done about Them? Shall I Have My Face Back at the End of Treatment?  
288 Are There Any Risk Factors for a Progressive and Severe Graves’ Orbitopathy?  
289 Can I Contact Patient Support Groups or Fellow Patients?  
289 If Graves’ Orbitopathy Is an Autoimmune Disease, Does That Mean My Immune System Is Collapsed?  
290 After Orbital Radiation, When Will It Be Possible to Have a Baby?
291 Atypical Manifestations
Daumerie, C. (Brussels); Fichter, N. (Olten)

What Are the Atypical Manifestations of Graves’ Orbitopathy?
What Are Other Diseases Mimicking Unilateral or Atypical Graves’ Orbitopathy?
Are the Clinical Presentation and Management of Unilateral Different from Bilateral Graves’ Orbitopathy?
What Is the Prevalence of Unilateral Graves’ Orbitopathy?
Can We Predict the Course of Unilateral Graves’ Orbitopathy?
What Is Euthyroid/Hypothyroid Graves’ Orbitopathy?
How Will You Manage Euthyroid/Hypothyroid Graves’ Orbitopathy?
What Is Globe Subluxation?
Can Graves’ Orbitopathy Patients without Muscle Swelling Be at Risk for Loss of Vision due to Optic Neuropathy?
References

301 Childhood Graves’ Orbitopathy
Bartalena, L. (Varese)

How Frequent Is Graves’ Orbitopathy in Children?
Are Signs and Symptoms of Graves’ Orbitopathy in Childhood Similar to Those in Adulthood?
Why Is Graves’ Orbitopathy in Children and Adolescents Milder than in Adults?
What Medical Treatment for Graves’ Orbitopathy in Children and Adolescents?
What Modality of Treatment for Hyperthyroidism in Children/Adolescents with Graves’ Orbitopathy?
What about Orbital Decompression in Childhood?
References

309 Comorbidity in Graves’ Orbitopathy
Žarković, M., Knežević, M. (Belgrade)

What Is the Risk of Diabetes Mellitus in Graves’ Orbitopathy?
What Is the Risk of Osteoporosis in Graves’ Orbitopathy?
What Is the Risk of Mental Disorders in Graves’ Orbitopathy?
What Is the Risk of Dry Eye Syndrome in Graves’ Orbitopathy?
What Is the Risk of Glaucoma in Graves’ Orbitopathy?
What Is the Risk of Cataract in Graves’ Orbitopathy?
What Is the Risk of Retinopathy in Graves’ Orbitopathy?
References

322 Prevention
Marcocci, C.; Marinò, M. (Pisa)

What Is Primary, Secondary, and Tertiary Prevention?
What Variables Can Be Modified in the Prevention of Graves’ Orbitopathy?
What Can Be Done in Primary and Secondary Prevention of Graves’ Orbitopathy?
What Can Be Done in Tertiary Prevention of Graves’ Orbitopathy?
What Should One Do when Talking to a Graves’ Orbitopathy Patient Who Smokes?
References
Preface to the Third, Revised and Expanded Edition

It is precisely 10 years ago that the first edition of *Graves’ Orbitopathy: A Multidisciplinary Approach* was published. The book has become rather popular, warranting a third edition. What has not changed is the successful question-and-answer format of the book. Also, although authors have changed, all are members of EUGOGO adhering to a multidisciplinary approach in the management of Graves’ orbitopathy (GO), preferably in combined thyroid-eye clinics. These EUGOGO principles have been widely adopted, and combined thyroid-eye clinics are now found all over Europe.

Much has happened in the field of GO in the last 10 years. Patients present now with less severe and less active disease than in the past. Presumably this is related to a secular decline in the prevalence of smoking, and to an earlier diagnosis and treatment of associated Graves’ hyperthyroidism. Novel immunosuppressive treatment modalities have become available. Patient-reported outcomes and the socioeconomic consequences of GO have been given more attention. Actually, we have obtained a better understanding of almost all aspects of GO, and that is duly reflected in the updated text. New chapters have been added on several topics, dealing with comorbidity (diabetes, osteoporosis, dry eye syndrome, glaucoma, cataract, retinopathy), local treatment modalities (artificial tears, prisms, botulinum toxin), novel immunosuppressive treatments (rituximab, teprotumumab, tocilizumab), protocols (selenium, glucocorticoids, retrobulbar irradiation, cyclosporine, rituximab), and questions frequently asked by patients (the patient’s view).

New centres have become EUGOGO members. EUGOGO remains active in performing clinical and basic research studies, and in organizing annual GO teaching courses with real-life investigation of patients. Formal ETA/EUGOGO guidelines on the management of GO were published in 2016. The third edition of this book reflects very well the continuous activity inside and outside the EUGOGO group on this peculiar thyroid eye disease, which is still one of the remaining enigmas in the field of autoimmune thyroid diseases.

On behalf of EUGOGO,

*Wilmar M. Wiersinga*, Editor

*George J. Kahaly*, Co-Editor

Amsterdam and Mainz, June 2017
Preface to the Second, Revised Edition

The first edition of *Graves' Orbitopathy: A Multidisciplinary Approach* was very well received. We are grateful for the many pieces of positive feedback and constructive comments from our readers. The multidisciplinary approach and the question-and-answer format appear to be a highly successful formula, warranting a second edition of the book within 3 years of the first.

All chapters have been thoroughly updated, and it is gratifying to see how much progress has been made not only in better understanding the pathogenesis of Graves' orbitopathy, but also in its treatment. The EUGOGO consensus statement on the management of Graves' orbitopathy has been accepted worldwide as a useful guideline and is now fully incorporated in the text. Two new chapters have been added: one describing the socioeconomic impact of the disease and the other outlining the Amsterdam Declaration on Graves' orbitopathy. This declaration, aiming to improve outcomes for thyroid eye disease, was signed by 82 national and international organizations in the field of thyroidology and ophthalmology at the International Symposium on Graves’ Orbitopathy held in October 2009 in Amsterdam on the occasion of the 10th anniversary of EUGOGO.

We hope the second edition will again contribute to improvements in the quality of care delivered by health professionals to patients with Graves' orbitopathy.

On behalf of EUGOGO,
Wilmar M. Wiersinga, Editor
George J. Kahaly, Co-Editor
Amsterdam and Mainz, June 2010

Preface to the First Edition

We are very pleased to present *Graves' Orbitopathy: A Multidisciplinary Approach*.

The title of the book is a reflection of our opinion that real progress can be made in understanding thyroid eye disease and in improving the outcome of the disfiguring and often invalidating eye changes associated with Graves’ orbitopathy only if specialists of various disciplines work closely together. In other words, we favour a multidisciplinary approach in which internists/endocrinologists, ophthalmologists/orbital surgeons and basic scientists combine their forces. This has been the philosophy since the foundation of EUGOGO, the European Group on Graves’ Orbitopathy, in 1999. The group is currently composed of 13 centres in 8 European countries (Belgium, France, Germany, Greece, Italy, the Netherlands, Switzerland, and the United Kingdom), and, in accordance with our philosophy, each centre is represented by specialists in internal medicine and ophthalmology. A further requirement of EUGOGO membership is that each participating centre must have combined thyroid-eye clinics in which the patient can be seen simultaneously by physicians from both disciplines. It is gratifying to note that the number of combined thyroid-eye clinics has been increasing slowly but steadily throughout Europe over the last decade, thereby enhancing the quality of patient care.
EUGOGO meets twice a year, and we have had many lengthy and at times heated discussions on how to assess the eye changes in a most objective manner and what the best treatment should be. It has taken us several years to reach an acceptable degree of agreement among ourselves, again illustrating the many pitfalls in the management of Graves’ orbitopathy as well as the importance of using a multidisciplinary approach. Only then could we embark on prospective clinical trials (the size of the group allows completion of clinical studies in a much shorter time than possible for each individual centre), on teaching courses how to investigate and treat the patient with Graves’ orbitopathy (so far 3 courses have been held – Thessaloniki 2005, Pisa 2006, and Mainz 2007), and on papers in scientific journals describing the outcome of our studies and recommendations on disease management.

The present book reflects our current thinking on Graves’ orbitopathy: all authors are EU-GOGO members. The internal consistency between chapters is the result of our ongoing discussions during the annual EUGOGO meetings. The outline of the book is unusual by its choosing the question-and-answer format. The purpose is to enable the book to be also used as a quick reference source for the practising physician confronted with an ordinary or extraordinary management question: most likely the answer can be found in one of the 194 questions asked in this book. We do not apologize for some overlap between chapters (especially on smoking and thyroid treatment), because these issues are relevant to many aspects of Graves’ orbitopathy and it facilitates fast retrieval of the information you are looking for. Topics such as unilateral eye disease, childhood Graves’ orbitopathy, and disease-specific quality-of-life assessment which are not easily found elsewhere receive the attention they deserve. The editors welcome feedback from the readership: please send your comments to us, also on how future editions could be improved. You may also consult the EUGOGO website (www.eugogo.eu).

We would like to thank the patients with Graves’ orbitopathy who cooperated in our endeavours to better understand their disease. We also thank S. Karger AG, Medical and Scientific Publishers, for their efforts to edit, produce, and publish the book within a very short time. Last but not least, we are grateful to the authors for their excellent contributions. It again proves how much can be accomplished by a group of dedicated people.

Wilmar M. Wiersinga, President EUGOGO, Editor
George J. Kahaly, Treasurer EUGOGO, Co-Editor
Amsterdam and Mainz, June 2007